Patient group | Age | Sex | Pathology/COD | Tissue used | Seizure frequency | iEcOG spikes | Anti-epileptic drugs | Engel score (1 yr) |
---|---|---|---|---|---|---|---|---|
1) Control | 73 | F | subdural hematoma | HC | NA | NA | NA | NA |
2) Control | 58 | M | unknown. ALS patient | HC & CX | NA | NA | NA | NA |
3) Control | 62 | M | unknown, non-demented control | HC & CX | NA | NA | NA | NA |
4) Control | 94 | F | CVA | HC & CX | NA | NA | NA | NA |
5) Control | 71 | M | pancreas carcinoma | HC & CX | NA | NA | NA | NA |
6) Control | 64 | F | respiratory failure | HC & CX | NA | NA | NA | NA |
7) Control | 70 | M | sepsis with broncopneumonia | HC | NA | NA | NA | NA |
8) Control | 50 | F | metastasized broncocarcinoma | HC & CX | NA | NA | NA | NA |
9) Control | 48 | M | DMT I induced organ failure | HC | NA | NA | NA | NA |
10) Control | 74 | M | pulmonary carcinoma | HC & CX | NA | NA | NA | NA |
11) Control | 62 | F | renal carcinoma (euthanasia) | CX | NA | NA | NA | NA |
12) Control | 93 | F | heart failure | CX | NA | NA | NA | NA |
13) Control | 92 | F | cachexia/dehydration | CX | NA | NA | NA | NA |
14) non-HS | 45 | M | W0, FCD type1 to 2A in cortex | HC | 6 | CX | LTG, PHT | 1A |
15) non-HS | 46 | F | W0, MCD type 1 in cortex | HC | 12 | CX | CBZ, VPA | 1A |
16) non-HS | 46 | M | W0, epilepsy after head trauma | HC | 90 | HC & CX | CBZ, VPA, TPR | 1B |
17) non-HS | 42 | F | W0, DNT WHO grade I | HC & CX | 1 | CX | CBZ, LTG, LEV | 1A |
18) non-HS | 34 | F | W0, cortical cavernoma | HC | 1.5 | HC & CX | CBZ | 1A |
19) non-HS | 40 | F | W0, MCD type 1 in cortex | HC | 8 ( C ) | HC & CX | LEV, LTG, CBZ | 1A |
20) non-HS | 43 | F | W0, therapy resistant epilepsy | HC & CX | 40 ( C ) | HC & CX | PHT, LTG | 1A |
21) non-HS | 47 | M | W0, therapy resistant epilepsy | HC | 30 | HC | CBZ, VPA, LTG, LEV | 3A |
22) non-HS | 28 | M | W0, MCD type 1 in cortex | HC | 60 | HC & CX | CBZ, TPR. | 1A |
23) non-HS | 54 | M | W0, ganglioglioma WHO grade I | HC & CX | 1.5 | HC & CX | OXC, LTG, CLO | 1A |
24) non-HS | 30 | M | W0, therapy resistant epilepsy | CX | 8 | HC & CX | OXC, LEV, CLO | 1A |
25) non-HS | 37 | F | W0, therapy resistant epilepsy | CX | 1 | not measured | LTG, CLO | 1A |
26) non-HS | 61 | M | W0, therapy resistant epilepsy | CX | 5.5 | HC & CX | PHT, CBZ | 2A |
27) non-HS | 19 | M | W0, ganglioglioma WHO grade II | CX | 1 | None | VPA, LEV | 1A |
28) non-HS | 27 | F | W0, therapy resistant epilepsy | CX | 16 | HC & CX | LEV | 1A |
29) non-HS | 46 | M | W0, cavernoma in uncus | CX | 60 | HC | CBZ, VPA, OXC, LEV, LTG | 1A |
30) non-HS | 44 | M | W0, therapy resistant epilepsy | CX | 18 | HC & CX | TPR, OXC | 1A |
31) HS | 41 | M | MTS W4 | HC & CX | 12 | not measured | PHT, CLO, CBZ, LTG | 1A |
32) HS | 44 | F | MTS W2 | HC | 8 ( C ) | not measured | CBZ, OXC, CLO | 1A |
33) HS | 41 | M | MTS W4 | HC | 3 | not measured | CBZ | 1A |
34) HS | 52 | F | MTS W4 | HC & CX | 10 | not measured | CBZ, CLO, DZP | 2D |
35) HS | 50 | M | MTS W4 | HC | 18 | not measured | CBZ, GBP | 2A |
36) HS | 36 | F | MTS W4 | HC & CX | 2 | not measured | OXC, LZP | no info |
37) HS | 42 | M | MTS W4 | HC & CX | 2 | not measured | LEV, LTG | 2A |
38) HS | 36 | M | MTS W4 | HC & CX | 10 | HC & CX | OXC, PGB | 1B |
39) HS | 49 | F | MTS W4 | HC | 8 ( C ) | not measured | OXC, CLO | 1A |
40) HS | 42 | F | MTS W4 | HC | 4.5 | not measured | LEV, LTG, PBT | 1A |
41) HS | 36 | M | MTS W4 | CX | 5 | not measured | PGB, LTG | 1A |
42) HS | 34 | F | MTS W4 | CX | 10 ( C ) | HC & CX | LTG, CBZ, VPA,CLO | 2A |
43) HS | 49 | M | MTS W3 | CX | 1 | None | LTG, CBZ, CLO | 1A |
44) HS | 45 | M | MTS W4 | CX | 0.5 | not measured | GBP, LTG | 1A |
45) HS | 48 | M | MTS W4 | CX | 3.5 | not measured | CBZ, LTG, VPA | 1A |